and have shown to be advantageous over traditional treatments using antibodies, peptides and nanoparticles because of better bio-distribution, tumor affinity, tumor penetration, clearance from the body and lower in vivo degradation. Peptoids may also reduce the toxic side effects of anti-cancer drugs, and likely can reduce the cost of cancer treatment. Peptoids (up to ~50 amino acids in length) contain controlled sequence composition and diverse side chains, and usually have a peptide-based backbone and N-substituted glycines (Figure 1 ). Like the alpha carbon of peptides, the side chain of peptoids are placed on the nitrogen atom of the amide group. Peptoids like PMC (2,2,5,7,8-pentamethylchroman-6-sulphonyl) have protected guanidinopropyl amine monomer. These were first described by the Zuckermann group, and further modified by Annelise Barron et al., to generate PMC, a mixed guanido/amino linear peptoid (5, 6) . However, their poor solubility resulted in low coupling efficiency and the extended cleavage time essential for the PMC group led to acid-induced degradation of the mixed peptoids. Sub-monomer peptoid synthesis uses conventional solid-phase approach (on resin beads) ( Figure 2 ). Introduction of both lysine-type and argininetype monomers within the same sequence has modeled a new strategy for synthesis of effective peptoids (7) . Also by using the protocol developed by Jonathan Rothbard et al, new polyarginine-type peptoids have been synthesized and to improve bio-molecular recognition of targets, an organic moiety is added to the backbone structure (8) . Furthermore, new polymeric peptoids that spontaneously attain distinct supramolecular structures are effectively being used for the synthesis of designer drugs for the treatment of different diseases including cancer.
RECENT ADVANCEMENTS IN PEPTOID DESIGN AND SYNTHESIS
Variations in the secondary, tertiary, and random structures of peptide-like oligomers were designed by several groups for generating different landscapes of peptoid structure. These modifications conferred disease-specificity to the peptoids. Additionally, the creation of effective peptoids have inspired and guided protein expression, protein-protein interaction, and protein folding. Recently, Robertson et al, have successfully designed peptoid nanosheets which can target specific proteins and serve distinct functionalities (9) . Computational tools have aided in the generation of efficient non-biological synthetic heteropolymeric peptoids (10, 11) . Every design utilizes the accurate force fields to understand the complex peptoid architectures. Properly designed peptoids are efficiently synthesized using a solidphase and solution-phase approach. In solid-phase method, synthesis of polypeptoids up to ~50 units in length has shown excellent yield, and has allowed for incorporation of various side chains with controlled sequence composition (4, 12) . This method is further improved by successful incorporation of amine derivatives of heterocycles such as histamine, pyridine, and tryptamine (13) . On the other hand, in solutionphase synthesis, bromoacetylbromide is used for acylation reaction with the N-terminus of the peptoid chain. In most cases, several cycles of filtration, evaporation, and chromatography have been applied to produce reasonably large quantities of peptoids (14) . Advancement of solution-phase synthesis method is achieved by "Ugi four components reaction (4-CR)" in which a primary amine, a carboxylic acid, an isocyanide, and an oxo compound react to form a dipeptoid backbone (15) . This process generates macrocyclically diversified peptoid polymers of stable secondary structures to mimic native protein. As a result, complex structures consisting of long chains within a single type of polymer have been successfully developed to create helix bundles comprising of hydrophobic cores (16) . Binding of high affinity zinc into the peptoid two-helix bundles has also been introduced for improvement in peptoidal mimicry of biological proteins (17) . Therefore, innovative methods, computational designs, and synthetic approaches, have revolutionized the peptoid chemistry and have led to the development of more complicated protein-like structures targeting specific proteins.
BIOLOGICAL APPLICATIONS OF PEPTOIDS IN CANCER

Application of peptoids in cancer diagnosis
Peptoids have been used as a tool in cancer imaging and diagnosis. For example, (MRI) (19) . In another study, a peptoid-based positron emission tomography (PET) tracer was used for imaging of VEGFR expression in prostate cancer (19, 20) . Passos © 1996-2017 et al, described the synthesis of fluorophore labeled peptoids using the Ugi multicomponent reaction and demonstrated internalization and localization of fluorescent peptoids in breast cancer cells (4-CR) (21) . Because caspase-3 is increased in cancer, in situ monitoring of caspase-3 activity has been proposed as a means for cancer diagnosis (22) . For detection and quantification of caspase-3 activity, Pérez-López et al desribed the use of FRET-based fluorogenic substrates against caspase-3 conjugated to the cell permeable cationic peptoids (23) . Together, such studies establish the role of fluorescent peptoids and fluorescent molecule tagged peptoids as a prominent and promising approach in cancer diagnosis.
Application of peptoids in cancer treatment
Peptoids exhibit high bioactivity as protein mimics, which, in turn, can reduce the dose of antioncogenic antibodies required in the treatment of cancer. Additionally, peptoids can also replace the use of small molecules developed for cancer treatment (Figures 4 and 5) . Moreover, generation of large combinatorial libraries of such peptoids provide the options of high throughput screening and effective selection of the anti-oncogenic peptoids. Peptoid libraries are usually generated by the "split-pool" approach, which direct the development of 'one-bead one compound' libraries with huge diversity (24) (25) (26) (27) . Thomas Kodadek et al showed that cells are permeable to most peptoids. In their work, the group applied peptoids to the biological systems and proved their therapeutic efficacy (28).
Many peptoids have been found to be effective, even at low doses, in the treatment of a broad range of cancer cell lines and multidrug resistant cancer cells. Cationic, amphipathic peptoids were shown to have a significant inhibitory effect on tumor growth in a human breast cancer xenotransplantation model (29) . In addition to these studies, homodimers, homotrimers, and heterodimers of peptoids have been shown to interact with biological targets present on the surface of the lung cancer cells (30) . Lee et al, used a peptide-peptoid hybrid in the treatment of prostate cancer cells (31) . Peptide-peptoid hybrid PPS1D1 has been shown to have anti-lung cancer activity (32) . Desai et al, showed that the peptoid, PPS1D1, enhanced the efficacy of docetaxel in mice bearing H460 lung cancer xenografts (33) .
Among the cell cycle regulatory proteins, the loss of action of the tumor suppressor protein, p53, is involved in oncogenic progression. Loss of regulatory function is largely due to mutations and the inactivation of the cell cycle check points controlled by wild type p53 (34, 35) . Also, in cancer cells, overexpressed Human Double Minute 2 (HDM2) factor binds to p53 protein and inactivates its function leading to tumor aggressiveness and drug resistance. Therefore, Toshiaki Hara et al have used for targeting p53 signaling network with peptoid as a treatment strategy by designing and optimizing oligomeric peptoids that target HDM2-p53 interaction (36) . AKT is one of the most commonly activated signaling pathways in various types of human cancer (37) . AKT is a Ser/Thr kinase which transduces signals from growth factors to downstream targets that control tumor development. Peptoids have been shown to be highly selective due to their extensive interactions with the specific substrate binding site (38) . Peptoids have been also used for inhibition of angiogenesis by targeting VEGF receptor-2 (VEGFR2) which causes reduced angiogenesis and hence tumor development (39) . Peptoid-based cap groups (Cal27 CisR) that inhibit HDAC6 activity have shown enhanced chemosensitizing properties and led to reversion of the cisplatin resistance in squamous carcinoma cells (40) .
Targeting RNA with peptoids is a novel strategy in cancer treatment (41) . Some of such peptoids have been identified by high-throughput screening of peptoid library. Peptoid scaffolds with RNA binding moieties have been used in microarrays, to screen, profile, and quantify their interactions with RNA-binding molecules (42, 43) . For example, peptoid microarrays are used to identify specific ligand for the RNA hairpin precursor of miR-21, a microRNA, which is up-regulated in different forms of solid tumors (44) .
